MedTrace Logo

Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.

NCT00091585 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2007-05-10

No results posted yet for this study

Summary

The purpose of this study is to determine whether SNS-595 given intravenously once every 3 weeks is safe.

Conditions

  • Neoplasms

Interventions

DRUG

SNS-595

Sponsors & Collaborators

  • Sunesis Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Daniel C. Adelman, MD · Sunesis Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Completion
2006-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00091585 on ClinicalTrials.gov